Balyasny Asset Management
LXEO icon

Balyasny Asset Management’s Lexeo Therapeutics LXEO Stock Holding History

Balyasny Asset Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.12M Sell
1,589,585
-45,441
-3% -$322K 0.01% 1076
2025
Q4 		$16.2M Sell
1,635,026
-2,278,762
-58% -$20.8M 0.02% 824
2025
Q3 		$26M Sell
3,913,788
-95,349
-2% -$461K 0.03% 600
2025
Q2 		$16.1M Buy
+4,009,137
New +$13.2M 0.02% 754

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's LXEO Position: Q1 2026 in Review

Balyasny Asset Management reduced its Lexeo Therapeutics (LXEO) stake by 2.8% in Q1 2026, selling an estimated $322K and leaving 1,589,585 shares worth $9.12M. The position accounts for 0.01% of the portfolio, ranked #1076.

Balyasny Asset Management first reported a position in LXEO in Q2 2025 and has held it in 4 quarters since. The position peaked at $26M in Q3 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Balyasny Asset Management held 1,589,585 shares of Lexeo Therapeutics worth $9.12M as of Q1 2026.
  • Balyasny Asset Management sold 45,441 Lexeo Therapeutics shares in Q1 2026, an estimated $322K.
  • Lexeo Therapeutics made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1076 holding.
  • Balyasny Asset Management first reported a position in Lexeo Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Balyasny Asset Management's Lexeo Therapeutics position peaked at $26M in Q3 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.